Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection
Pejman Solaimani1, Christopher Hogan2, 3, Matthew Chin2, 3, Juan L Miranda4, Douglas L Nguyen2, 3, *
Identifiers and Pagination:Year: 2016
Issue: Suppl 1: M3
First Page: 58
Last Page: 69
Publisher ID: MEDJ-3-58
Article History:Received Date: 12/01/2014
Revision Received Date: 12/06/2015
Acceptance Date: 25/06/2015
Electronic publication date: 29/07/2016
Collection year: 2016
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
With 5.2 million people living with Hepatitis C, it is the most common blood-borne infection in the United States. Untreated chronic HCV infection may result in adverse consequences such as cirrhosis, portal hypertension, hepatic failure and hepatocellular carcinoma. Previously approved treatments include Pegylated-interferon alpha-2a/2b plus ribavirin, Boceprevir and Telaprevir. Recently approved medications include Sofosbuvir (SOF), Simeprevir (SMV), Ledispavir-Sofosbuvir (Harvoni®) and Ombitasvir-paritaprevir-ritonavir with dasabuvir tablets (Viekira Pak). Here we review the literature describing the current and emerging therapies for chronic hepatitis C.